New hope for Tough-to-Treat lung cancer: can this combo extend life?
NCT ID NCT07361484
Summary
This global study is testing whether adding an experimental drug called plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. It's for patients whose cancer has worsened after trying immunotherapy and platinum-based chemo. About 442 participants will be randomly assigned to receive either the new combination or standard chemo alone to see which is more effective and safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.